Biodexa Pharmaceuticals (BDRX) Gains from Sales and Divestitures (2018)

Biodexa Pharmaceuticals (BDRX) reported Gains from Sales and Divestitures of $11.9 million for Q4 2018.

Biodexa Pharmaceuticals (BDRX) Gains from Sales and Divestitures (2018) Analysis & Trends

Biodexa Pharmaceuticals (BDRX) has 1 years of Gains from Sales and Divestitures data on file, last reported at $11.9 million in Q4 2018.

For the quarter ending Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $11.9 million; the trailing twelve-month figure through Dec 2018 stood at $11.9 million (changed N/A YoY), and the FY2019 full-year result was $1.2 million, down 90.22% from the prior year.
Gains from Sales and Divestitures steadied at $11.9 million in Q4 2018.
In the past five years, Gains from Sales and Divestitures ranged from a high of $11.9 million in Q4 2018 to a low of $11.9 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Biodexa Pharmaceuticals	18.43 Bn	18.43 Bn	-

Download Data

Date	Value
Dec 31, 2018	11.91 Mn
Dec 31, 2018	11.91 Mn